search
Back to results

Interactions of Medicine and Exercise With Meal Timing (MMET)

Primary Purpose

Metabolic Syndrome, Protection Against, Exercise Training, Metformin

Status
Recruiting
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Sponsored by
University of Castilla-La Mancha
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Metabolic Syndrome, Protection Against focused on measuring Cardiorespiratory fitness, Insulin sensitivity, Dyslipidemia, Hypertension

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Metabolic syndrome patients diagnosed according to The International diabetes federation consensus of 2009 (Alberti, et al., Circulation).

Exclusion Criteria:

  • Cardiovascular disease or musculo-skeletal that prevents them from being able to perform intense exercise.

    • Respiratory failure
    • Liver o renal disease
    • Pregnancy

Sites / Locations

  • University of Castilla-La Mancha (Exercise Physiology Lab)Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

No Intervention

Experimental

Experimental

Arm Label

NO EXERCISE TRAINING

EXERCISE TRAINING FED

EXERCISE TRAINING FASTED

Arm Description

25-32 individuals with metabolic syndrome that will remain sedentary during the 4 months of treatment taking their habitual medication (i.e., blood pressure, glucose, cholesterol, and triglycerides lowering drugs) and meals at the habitual time (CONTROL GROUP).

2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingesting a liquid test meal (500 calls, 50% fat) 30 min before exercise (EXERCISE TRAINING FED).

2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingestion of a placebo meal (0 kcals) 30 min before exercise (EXERCISE TRAINING FAST).

Outcomes

Primary Outcome Measures

Insulin sensitivity assessed using intravenous glucose tolerance test
Curves of insulin-mediated glucose clearance, inhibition of lipolysis, and liver glucose output measured with the use of stable isotope infusion.
Post-prandial lipemia assessed by an oral fat tolerance test
Rates of appearance and clearance of liver VLDL-TG, Apolipoprotein B, and fatty acids using stable isotopes.
Blood pressure assessed by ECG-gated automated sphygmomanometer
Determined immediately after treatments and during the following 24-h using ambulatory blood pressure Holter-type monitors.
Glycemic control assessed by 24-h continuous interstitial glucose monitoring
Determined by a patch glucose sensor paired with a glucose monitor.

Secondary Outcome Measures

Body composition.
Determined by bioelectrical impedance to calculate body fat mass and fat free mass.
Body mass index
Determined by body weight (kg) and height (m) to calculate body mass index (kg/m2)
Maximal oxygen consumption during a graded exercise test to exhaustion, assessed by indirect calorimetry
Calculation of cardiorespitarory fitness
Resting metabolic rate assessed by indirect calorimetry while lying after an overnight fast
Using indirect calorimetry and a ventilated canopy system
Maximal rate of fat oxidation assessed by indirect calorimetry during a submaximal exercise test.
Calculated in grams per min during the incremental cycle ergometer test with the use of indirect calorimetry system
24-hour monitoring of blood concentrations of metformin, statins, and angiotensin blockers assessed using gas chromatography-mass spectrometry.
To study the pharmacokinetics of the habitual medicines used by our subjects during the different experimental conditions
The activity of intramuscular proteins (enzymes) involved in energetics assessed using western blots.
Measured in skeletal muscle obtained by percutaneous muscle biopsy.

Full Information

First Posted
June 28, 2020
Last Updated
August 23, 2023
Sponsor
University of Castilla-La Mancha
Collaborators
Ministerio de Economía y Competitividad, Spain, Servicio de Salud de Castilla-La Mancha
search

1. Study Identification

Unique Protocol Identification Number
NCT04477590
Brief Title
Interactions of Medicine and Exercise With Meal Timing
Acronym
MMET
Official Title
Optimizing Exercise Training Effects on Metabolic Syndrome Factors by Altering the Timing of Medication and Meal Ingestion
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 7, 2022 (Actual)
Primary Completion Date
May 30, 2024 (Anticipated)
Study Completion Date
December 30, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Castilla-La Mancha
Collaborators
Ministerio de Economía y Competitividad, Spain, Servicio de Salud de Castilla-La Mancha

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
To analyze the effects of altering the time of ingestion of participants' habitual medication (i.e., metformin, statins, ARAII/IACE) and meals around the time of exercise training (exercise fasted or fed) on the improvement of metabolic syndrome factors (hypertension, insulin sensitivity, dyslipidemia, and obesity). There will be a preliminary study of the effects of training "time-of-day" on the primary study outcomes.
Detailed Description
Objective: The purpose is to study in a group of adults with metabolic syndrome and obesity, the effects of altering timing between exercise training, meals, and their habitual medication on the improvement in the factors that compose the metabolic syndrome (i.e., hypertension, insulin resistance, central obesity, and dyslipidemia). The main objective is to find the most productive combination between exercise training and the timing of their habitual pharmacological treatment, and meal ingestion for lowering those factors. Methods and design: Cross-over randomized double-blinded, pretest-posttest control group experimental design. The project will be developed in a single center with the collaboration of the regional public health system (SECAM). There will be a preliminary study of the effects of training "time-of-day" on three parallel groups of individuals. Subjects: Will be referred by their primary care physicians to our study unit or recruited by advertisements in local media. Up to 180 subjects, all of them with metabolic syndrome will be recruited (>25% women). Measurements: Specifically, we will study if the cardiovascular and metabolic adaptations to aerobic training that result in amelioration of metabolic syndrome factors are potentiated by correct timming of training, meals, and medicine around exercise training time.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Metabolic Syndrome, Protection Against, Exercise Training, Metformin, Statins, Angiotensin-Converting-Enzyme Inhibitor, Fasting, Intermittent, Angiotensin Hypertension
Keywords
Cardiorespiratory fitness, Insulin sensitivity, Dyslipidemia, Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Cross-over randomized, pretest-posttest control group experimental design.
Masking
ParticipantInvestigator
Masking Description
Habitual medicine will be embedded in bigger capsules along with a placebo to be able to randomly allocate medicine/placebo. The first meal in the morning will be also masked by either providing a non-caloric or caloric vanilla-flavored beverage resulting in the fed/fasted condition in a blinded fashion.
Allocation
Randomized
Enrollment
160 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
NO EXERCISE TRAINING
Arm Type
No Intervention
Arm Description
25-32 individuals with metabolic syndrome that will remain sedentary during the 4 months of treatment taking their habitual medication (i.e., blood pressure, glucose, cholesterol, and triglycerides lowering drugs) and meals at the habitual time (CONTROL GROUP).
Arm Title
EXERCISE TRAINING FED
Arm Type
Experimental
Arm Description
2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingesting a liquid test meal (500 calls, 50% fat) 30 min before exercise (EXERCISE TRAINING FED).
Arm Title
EXERCISE TRAINING FASTED
Arm Type
Experimental
Arm Description
2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingestion of a placebo meal (0 kcals) 30 min before exercise (EXERCISE TRAINING FAST).
Intervention Type
Drug
Intervention Name(s)
EXERCISE TRAINING WITH OR WITHOUT MEDICATION
Other Intervention Name(s)
Exercise timing with respect to medication (metformin, statins, ARAII/ACEI)
Intervention Description
A group will train 30 min after taking their habitual dose of medicine (MEDICATED train) while another group will train after taking a placebo (NON-MEDICATED train) and will receive their medication after training.
Primary Outcome Measure Information:
Title
Insulin sensitivity assessed using intravenous glucose tolerance test
Description
Curves of insulin-mediated glucose clearance, inhibition of lipolysis, and liver glucose output measured with the use of stable isotope infusion.
Time Frame
12 months
Title
Post-prandial lipemia assessed by an oral fat tolerance test
Description
Rates of appearance and clearance of liver VLDL-TG, Apolipoprotein B, and fatty acids using stable isotopes.
Time Frame
12 months
Title
Blood pressure assessed by ECG-gated automated sphygmomanometer
Description
Determined immediately after treatments and during the following 24-h using ambulatory blood pressure Holter-type monitors.
Time Frame
12 months
Title
Glycemic control assessed by 24-h continuous interstitial glucose monitoring
Description
Determined by a patch glucose sensor paired with a glucose monitor.
Time Frame
36 months
Secondary Outcome Measure Information:
Title
Body composition.
Description
Determined by bioelectrical impedance to calculate body fat mass and fat free mass.
Time Frame
12 months
Title
Body mass index
Description
Determined by body weight (kg) and height (m) to calculate body mass index (kg/m2)
Time Frame
12 months
Title
Maximal oxygen consumption during a graded exercise test to exhaustion, assessed by indirect calorimetry
Description
Calculation of cardiorespitarory fitness
Time Frame
12 months
Title
Resting metabolic rate assessed by indirect calorimetry while lying after an overnight fast
Description
Using indirect calorimetry and a ventilated canopy system
Time Frame
12 months
Title
Maximal rate of fat oxidation assessed by indirect calorimetry during a submaximal exercise test.
Description
Calculated in grams per min during the incremental cycle ergometer test with the use of indirect calorimetry system
Time Frame
12 months
Title
24-hour monitoring of blood concentrations of metformin, statins, and angiotensin blockers assessed using gas chromatography-mass spectrometry.
Description
To study the pharmacokinetics of the habitual medicines used by our subjects during the different experimental conditions
Time Frame
36 months
Title
The activity of intramuscular proteins (enzymes) involved in energetics assessed using western blots.
Description
Measured in skeletal muscle obtained by percutaneous muscle biopsy.
Time Frame
36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Metabolic syndrome patients diagnosed according to The International diabetes federation consensus of 2009 (Alberti, et al., Circulation). Exclusion Criteria: Cardiovascular disease or musculo-skeletal that prevents them from being able to perform intense exercise. Respiratory failure Liver o renal disease Pregnancy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ricardo Mora-Rodriguez, PhD
Phone
925268800
Email
ricardo.mora@uclm.es
First Name & Middle Initial & Last Name or Official Title & Degree
Juan F Ortega, MD, PhD
Phone
925268800
Email
juanfernando.ortega@uclm.es
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
RICARDO M Mora-Rodriguez, PhD
Organizational Affiliation
University of Castilla-La Mancha
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Castilla-La Mancha (Exercise Physiology Lab)
City
Toledo
ZIP/Postal Code
45071
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ricardo Mora-Rodriguez, PhD
Phone
92526800
Ext
5515
Email
ricardo.mora@uclm.es
First Name & Middle Initial & Last Name & Degree
Juan F Ortega, MD, PhD
Phone
+3492526800
Ext
5515
Email
juanfernando.ortega@uclm.es
First Name & Middle Initial & Last Name & Degree
Juan F Ortega, MD, PhD
First Name & Middle Initial & Last Name & Degree
Ricardo Mora-Rodriguez, PhD

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
Upon reasonable request
Citations:
PubMed Identifier
24682492
Citation
Ortega JF, Hamouti N, Fernandez-Elias VE, de Prada MV, Martinez-Vizcaino V, Mora-Rodriguez R. Metformin does not attenuate the acute insulin-sensitizing effect of a single bout of exercise in individuals with insulin resistance. Acta Diabetol. 2014 Oct;51(5):749-55. doi: 10.1007/s00592-014-0580-4. Epub 2014 Mar 29.
Results Reference
background
PubMed Identifier
26667921
Citation
Mora-Rodriguez R, Ortega JF, Guio de Prada V, Fernandez-Elias VE, Hamouti N, Morales-Palomo F, Martinez-Vizcaino V, Nelson RK. Effects of Simultaneous or Sequential Weight Loss Diet and Aerobic Interval Training on Metabolic Syndrome. Int J Sports Med. 2016 Apr;37(4):274-81. doi: 10.1055/s-0035-1564259. Epub 2015 Dec 14.
Results Reference
background
PubMed Identifier
32598033
Citation
Alvarez-Jimenez L, Moreno-Cabanas A, Ramirez-Jimenez M, Morales-Palomo F, Ortega JF, Mora-Rodriguez R. Effects of statins and exercise on postprandial lipoproteins in metabolic syndrome vs metabolically healthy individuals. Br J Clin Pharmacol. 2021 Mar;87(3):955-964. doi: 10.1111/bcp.14447. Epub 2020 Jul 12.
Results Reference
background
PubMed Identifier
31925809
Citation
Mora-Rodriguez R, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M, Moreno-Cabanas A. Effects of statin therapy and exercise on postprandial triglycerides in overweight individuals with hypercholesterolaemia. Br J Clin Pharmacol. 2020 Jun;86(6):1089-1099. doi: 10.1111/bcp.14217. Epub 2020 Feb 18.
Results Reference
background
PubMed Identifier
31875915
Citation
Morales-Palomo F, Ramirez-Jimenez M, Ortega JF, Moreno-Cabanas A, Mora-Rodriguez R. Exercise Training Adaptations in Metabolic Syndrome Individuals on Chronic Statin Treatment. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgz304. doi: 10.1210/clinem/dgz304.
Results Reference
background
PubMed Identifier
31821339
Citation
Guio de Prada V, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M, Moreno-Cabanas A, Mora-Rodriguez R. Women with metabolic syndrome show similar health benefits from high-intensity interval training than men. PLoS One. 2019 Dec 10;14(12):e0225893. doi: 10.1371/journal.pone.0225893. eCollection 2019.
Results Reference
background
PubMed Identifier
31746500
Citation
Moreno-Cabanas A, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M, Mora-Rodriguez R. Importance of a verification test to accurately assess V̇O2 max in unfit individuals with obesity. Scand J Med Sci Sports. 2020 Mar;30(3):583-590. doi: 10.1111/sms.13602. Epub 2019 Dec 11.
Results Reference
background
PubMed Identifier
31415443
Citation
Morales-Palomo F, Ramirez-Jimenez M, Ortega JF, Mora-Rodriguez R. Effectiveness of Aerobic Exercise Programs for Health Promotion in Metabolic Syndrome. Med Sci Sports Exerc. 2019 Sep;51(9):1876-1883. doi: 10.1249/MSS.0000000000001983.
Results Reference
background
PubMed Identifier
31158474
Citation
Mora-Rodriguez R, Ortega JF, Ramirez-Jimenez M, Moreno-Cabanas A, Morales-Palomo F. Insulin sensitivity improvement with exercise training is mediated by body weight loss in subjects with metabolic syndrome. Diabetes Metab. 2020 Jun;46(3):210-218. doi: 10.1016/j.diabet.2019.05.004. Epub 2019 May 31.
Results Reference
background
PubMed Identifier
30459053
Citation
Mora-Rodriguez R, Ortega JF, Morales-Palomo F, Ramirez-Jimenez M. Weight loss but not gains in cardiorespiratory fitness after exercise-training predicts improved health risk factors in metabolic syndrome. Nutr Metab Cardiovasc Dis. 2018 Dec;28(12):1267-1274. doi: 10.1016/j.numecd.2018.08.004. Epub 2018 Aug 23.
Results Reference
background
PubMed Identifier
29771450
Citation
Ramirez-Jimenez M, Morales-Palomo F, Ortega JF, Mora-Rodriguez R. Effects of intense aerobic exercise and/or antihypertensive medication in individuals with metabolic syndrome. Scand J Med Sci Sports. 2018 Sep;28(9):2042-2051. doi: 10.1111/sms.13218. Epub 2018 Jun 4.
Results Reference
background

Learn more about this trial

Interactions of Medicine and Exercise With Meal Timing

We'll reach out to this number within 24 hrs